Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpiCept-NP-1
- Development stage
- Phase 3
- Lead developer
- EpiCept
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
EpiCept-NP-1 is a patented topical analgesic cream developed by EpiCept Corporation. It is a combination drug containing two FDA-approved drugs: 4% amitriptyline, a tricyclic antidepressant, and 2% ketamine, an NMDA receptor antagonist. This formulation was designed to provide effective, long-term relief from the pain associated with various peripheral neuropathies, including post-herpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), and chemotherapy-induced peripheral neuropathy (CPN). The topical route of administration aims to minimize systemic side effects and drug interactions.
- Brand names
- EpiCept NP-1
- Other names
- EpiCept™ NP-1 Topical Cream
02
Targets
5-HT2 (5-HT2 receptor family)ENT (Equilibrative nucleoside transporter family)ADRA1A (α1A)AChR (Acetylcholine receptor)HRH1 (Histamine H1 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)NET (Norepinephrine Transporter)MOR (Mu opioid receptor)SERT (Sodium-dependent serotonin transporter)ADRA1 (Alpha-1 adrenergic receptor family)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on EpiCept-NP-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiCept-NP-1.